Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05714202
Title A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (SunRISe-3)
Acronym SunRISe-3
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG


No variant requirements are available.